07:00 , Apr 23, 2012 |  BC Week In Review  |  Clinical News

EpiCept, GNI preclinical data

In mice with acute liver injury, IV F573 improved survival and led to a reduction in tumor necrosis factor (TNF) alpha and apoptosis vs. controls. Data were published in the Chinese Pharmacological Bulletin. EpiCept did...
07:00 , Jul 14, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Caspase-3 (CASP3; CPP32) Studies in mice and in human samples suggest inhibiting CASP3 could improve radiotherapy. In mice bearing human breast adenocarcinoma tumors, CASP3-deficient...
07:00 , Jul 21, 2008 |  BC Week In Review  |  Company News

EpiCept, GNI Ltd. deal

GNI received a license to develop and commercialize EpiCept’s EP1013 for late-stage viral hepatitis in Asia, Australia and New Zealand. The small molecule inhibitor of caspases is in preclinical development in the indication. GNI’s F351...